63 related articles for article (PubMed ID: 30549484)
1. Risks and benefits of clozapine and lithium co-prescribing: A systematic review and expert recommendations.
Verdoux H; Quiles C; de Leon J
Schizophr Res; 2024 Jun; 268():233-242. PubMed ID: 37002013
[TBL] [Abstract][Full Text] [Related]
2. Clozapine-induced agranulocytosis.
Mijovic A; MacCabe JH
Ann Hematol; 2020 Nov; 99(11):2477-2482. PubMed ID: 32815018
[TBL] [Abstract][Full Text] [Related]
3. Can lithium be used in the setting of clozapine commencement in patients with COVID-19 associated neutropenia: A case report.
Tan JQE; Dawson JL; Bastiampillai T
Clin Case Rep; 2024 Apr; 12(4):e8758. PubMed ID: 38617070
[TBL] [Abstract][Full Text] [Related]
4. Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia.
Qubad M; Bittner RA
Ther Adv Psychopharmacol; 2023; 13():20451253231158152. PubMed ID: 36994117
[TBL] [Abstract][Full Text] [Related]
5. Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review.
Corbeil O; Béchard L; Fournier É; Plante M; Thivierge MA; Lafrenière CÉ; Huot-Lavoie M; Brodeur S; Essiambre AM; Roy MA; Demers MF
J Psychopharmacol; 2023 Apr; 37(4):370-377. PubMed ID: 36794520
[TBL] [Abstract][Full Text] [Related]
6. Never Say Never: Successful Clozapine Rechallenge After Multiple Episodes of Neutropenia.
Shuman M; Moss L; Dilich A
Focus (Am Psychiatr Publ); 2021 Jan; 19(1):66-70. PubMed ID: 34483771
[TBL] [Abstract][Full Text] [Related]
7. Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series.
Béchard L; Corbeil O; Plante M; Thivierge MA; Lafrenière CÉ; Roy MA; Demers MF
J Psychopharmacol; 2021 Sep; 35(9):1152-1157. PubMed ID: 34229529
[TBL] [Abstract][Full Text] [Related]
8. Clozapine re-challenge and initiation following neutropenia: a review and case series of 14 patients in a high-secure forensic hospital.
Silva E; Higgins M; Hammer B; Stephenson P
Ther Adv Psychopharmacol; 2021; 11():20451253211015070. PubMed ID: 34221348
[TBL] [Abstract][Full Text] [Related]
9. Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals.
Flanagan RJ; Lally J; Gee S; Lyon R; Every-Palmer S
Br Med Bull; 2020 Oct; 135(1):73-89. PubMed ID: 32885238
[TBL] [Abstract][Full Text] [Related]
10. Clozapine rechallenge and initiation despite neutropenia- a practical, step-by-step guide.
Silva E; Higgins M; Hammer B; Stephenson P
BMC Psychiatry; 2020 Jun; 20(1):279. PubMed ID: 32503471
[TBL] [Abstract][Full Text] [Related]
11. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine.
Luykx JJ; Stam N; Tanskanen A; Tiihonen J; Taipale H
Br J Psychiatry; 2020 Sep; 217(3):498-505. PubMed ID: 31910911
[TBL] [Abstract][Full Text] [Related]
12. Mask Off? Lithium Augmentation for Clozapine Rechallenge After Neutropenia or Agranulocytosis: Discontinuation Might Be Risky.
Boazak M; Goldsmith DR; Cotes RO
Prim Care Companion CNS Disord; 2018 Nov; 20(6):. PubMed ID: 30549484
[No Abstract] [Full Text] [Related]
13. Lithium and clozapine rechallenge: a retrospective case analysis.
Kanaan RA; Kerwin RW
J Clin Psychiatry; 2006 May; 67(5):756-60. PubMed ID: 16841625
[TBL] [Abstract][Full Text] [Related]
14. Comment on "lithium and clozapine rechallenge: a retrospective case analysis".
Esposito D
J Clin Psychiatry; 2007 Apr; 68(4):635; author reply 635. PubMed ID: 17474825
[No Abstract] [Full Text] [Related]
15. A case of clozapine induced agranulocytosis 25 years after starting treatment: Effective use of lithium for augmentation in rechallenge.
Martina AC; Ee JS; Lamberti JS
Schizophr Res; 2019 Aug; 210():308-309. PubMed ID: 31277977
[No Abstract] [Full Text] [Related]
16. [Clozapine rechallenge after neutropenia in resistant schizophrenia: A review].
Simon L; Cazard F
Encephale; 2016 Aug; 42(4):346-53. PubMed ID: 27109327
[TBL] [Abstract][Full Text] [Related]
17. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.
Whiskey E; Taylor D
CNS Drugs; 2007; 21(1):25-35. PubMed ID: 17190527
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
